3430 Carmel Mountain Road, Suite 300
Tel: (858) 251-2100
45 articles with Neurelis, Inc.
STUDY PUBLISHED IN EPILEPSIA SHOWS SIGNIFICANT PROLONGATION OF TIME INTERVALS BETWEEN SEIZURE CLUSTERS TREATED WITH NEURELIS' VALTOCO® (DIAZEPAM NASAL SPRAY) CIV
Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates a significant increase in time between seizure clusters treated with VALTOCO® (diazepam nasal spray) CIV.
Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia.
NEURELIS PRESENTED CLINICAL DATA SUPPORTING SEIZURE CLUSTER INTERVAL ANALYSIS AT THE EPILEPSY FOUNDATION PIPELINE CONFERENCE
Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV.
NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE
Neurelis, Inc., today announced it will provide highlights of its clinical development program for VALTOCO® (diazepam nasal spray), an acute therapy for episodes of frequent seizure activity (seizure clusters), at the 16th EILAT Conference on New Antiepileptic Drugs and Devices, Madrid Spain, May 22-25, 2022.
DATA FROM NOVEL, EXPLORATORY ANALYSIS OF INTERMITTENT VALTOCO® (DIAZEPAM NASAL SPRAY) CIV USE INDICATES MORE THAN TWO-FOLD INCREASE IN MEAN INTERVAL BETWEEN SEIZURE CLUSTERS
Neurelis, Inc., today announced findings from a novel, exploratory analysis of VALTOCO® (diazepam nasal spray).
NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT SEIZURE ACTIVITY
Neurelis, Inc., announced that it has secured the issuance of United States Patent No. 11,241,414 (the '414 Patent) for VALTOCO® (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and pediatric patients age six and older.
Neurelis Announces Three Poster Presentations At The 2022 Annual Meeting Of The American Academy Of Neurology
Neurelis, Inc., will present three posters from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity in patients with epilepsy ages 6 to 65 at the 73rd Annual Meeting of the American Academy of Neurology, April 2 to 7, in Seattle, Wash.
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday.
NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION
Neurelis, Inc. announced that it has signed an exclusive licensing agreement with Aculys Pharma, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray) in Japan and the Asia-Pacific region which includes Australia, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Philippines, South Korea, Thailand and Vietnam.
Neurelis, Inc. will present a collection of 16 posters describing safety, tolerability and effectiveness results observed in trials evaluating VALTOCO® (diazepam nasal spray), and clinical trials designed to evaluate VALTOCO as a potential rescue therapy in patient groups with unmet needs at the annual meeting of the American Epilepsy Society December 3-7 in Chicago.
Neurelis Announces Addition of Brittany Bradrick as CFO and Expansion of Leadership Team and Board of Directors
Neurelis, Inc., announced today that it has made the following additions to its leadership team:
Neurelis, Inc. announced today that it is presenting two posters at the 50th Annual Meeting of the Child Neurology Society in Boston from September 29 through October 2.
Neurelis Initiates Study Of VALTOCO® (diazepam nasal spray) In Children With Seizure Clusters Aged Two To Five
Neurelis, Inc. announced today that it has initiated a clinical program to investigate the use of VALTOCO® (diazepam nasal spray) in children with epilepsy aged two to five as a treatment for seizure clusters.
Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds Targeting Cerebral Cavernous Malformations, A Rare CNS Disorder
Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc.
Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology
Neurelis, Inc., announced today that it is presenting five posters at the American Academy of Neurology (AAN) Annual Meeting being held virtually from April 17 through April 22.
Neurelis Announces Two Poster Presentations for the Annual Meeting of the Academy of Managed Care Pharmacy
Clinical studies support effectiveness and safety profile for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older
3/17/2021Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.
- 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company - Funds will enhance growth and commercial penetration of company's lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion - Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors
Neurelis, Inc., announced today the company has 12 posters being presented at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8.
Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults
Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4.